Dr. Jacob Kimmel is the President of NewLimit, a biotechnology company developing reprogramming medicines to treat age-related disease and extend human healthspan. Dr. Kimmel co-founded the company with Blake Byers and Bryan Armstrong, and has since raised over $300M from top venture capital funds like Kleiner Perkins, Dimension, Founders Fund, and Khosla Ventures. They expect to initiate their first clinical trial in a few years.
Dr. Kimmel has garnered a reputation as one of the brightest minds in longevity and the intersection between artificial intelligence and molecular biology, and NewLimit is often cited as one of the most important companies building in longevity today.
